<DOC>
	<DOCNO>NCT01770743</DOCNO>
	<brief_summary>The purpose study assess safety immunogenicity anthrax vaccine . The vaccine schedule dose also assess .</brief_summary>
	<brief_title>A Phase 2 Safety Immunogenicity Study Anthrax Vaccine Using 3 Schedules Two Dose Levels</brief_title>
	<detailed_description>The safety immunogenicity AV7909 post-exposure prophylaxis anthrax evaluate use randomize , parallel-group , active-controlled , double-blind design three immunization schedule two dose level healthy adult volunteer . Safety assess clinical laboratory test ( hematology , serum chemistry , urinalysis ) , monitor adverse event , vital sign , physical examination . Reactogenicity ( systemic injection site reaction ) assess subject use subject e-diaries 7 day immunization investigator in-clinic visit 7 14 day immunization , visit , applicable . Immunogenicity measure toxin neutralize antibody ( TNA ) response seroconversion rate .</detailed_description>
	<mesh_term>Anthrax</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Be 1850 year old Be good health Have access computer internet complete diary Agree abstain sex first 84 day study practice birth control woman able get pregnant Have donate blood previous 8 week A know anaphylactic response , severe systemic response , serious hypersensitivity reaction prior immunization . A history latex allergy . Have receive shot ( vaccine ) , include flu shot , past 6 week plan get shot 4 week last study shoot give . Have previously serve military time 1990 plan enlist military Screening Day 84 . Prior immunization anthrax vaccine , recombinant protective antigen ( rPA ) vaccine , know exposure anthrax organism . Have participate anthrax therapeutic vaccine study ( monoclonal antiPA anthrax immune globulin anthrax vaccine ) . Participation investigational study involve use pharmacological intervention within 30 day Screening visit planning participate study require dose 12month safety followup telephone call . Have know diagnosis immunodeficiency disease include limited : acquire immune deficiency syndrome ( AIDS ) , common variable immunodeficiency disease , immunoglobulin A ( IgA ) deficiency , hypogammaglobulinemia . Past history significant autoimmune disease rheumatoid arthritis , lupus erythematous , psoriasis area vaccination , require immunotherapy , glomerulonephritis , autoimmune thyroiditis . Have receive immunosuppressive therapy cytotoxic drug Rituximab within past 2 year . A history cytotoxic chemotherapy radiation therapy . Chronic ( &gt; 10 day ) daily oral parenteral corticosteroid therapy past 12 month . Any lung disease , include reactive airway disease , require daily use medication . A female currently breastfeed positive pregnancy test . A history drug alcohol abuse within 12 month prior Screening , positive result urine drug screen cocaine , marijuana , opiates , methamphetamine , benzodiazepine , oxycodone . Any tattoo skin condition deltoid region either arm may obscure assessment injection site . A medical condition , opinion PI designee , could adversely impact subject 's participation safety conduct study . Any plan elective inpatient surgery study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>post-exposure prophylaxis</keyword>
	<keyword>toxin neutralization assay</keyword>
</DOC>